A Phase 2 interventional study of Midomafetamine HCl and Lactose placebo pill in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 20th largest by enrollment, is the only one that started in 2004, is one of 28 in phase 2, and was the 1st registered.
2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 21–70
Sunstone Medical · Sites in United States
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 18–75
Johns Hopkins University · Sites in United States
Ages 21+
Bronx VA Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 30 · Phase 3 6
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 69 across 2,202 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 25 across the 38 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 15 (88%) have results posted.
Among the 20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2004, is one of 13 in phase 2, and was the 1st registered.
Resilient Pharmaceuticals’s Stress Disorders, Post-Traumatic studies by the year they started, since 2004.
4 of the studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT07569159Sunstone MedicalMDMA Therapy in Veterans With PTSD | 2027-04-01 |
| NCT05837845Patricia SuppesMDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | 2027-05 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Resilient Pharmaceuticals’s 20 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare MDMA-assisted therapy to placebo with therapy in people with chronic, treatment-resistant posttraumatic stress disorder (PTSD). The main question it aims to answer is: Is there a reduction in PTSD symptoms among people given MDMA-assisted therapy compared to placebo with therapy?
Participants will receive either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions spaced three to five weeks apart. During experimental sessions, participants receive an initial dose of 125 mg of MDMA HCl, or placebo, followed by a dose of 62.5 mg of MDMA HCl, or placebo. During this treatment period, participants will also undergo non-drug preparatory psychotherapy sessions and non-drug integrative sessions.
The study will test whether MDMA-assisted therapy can be safely given to participants. Researchers will compare PTSD symptoms in the MDMA-assisted therapy group to the placebo with therapy group to see if there is a reduction in symptoms after the treatment period.
This randomized, double-blind placebo-controlled pilot study assessed the safety and effectiveness of MDMA-assisted therapy among people with chronic, treatment-resistant PTSD, including veterans. Participants were assigned to receive either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions spaced three to five weeks apart during Stage 1 of the study. During these experimental sessions, participants received an initial dose of 125 mg of MDMA HCl followed by a supplemental dose of 62.5 mg of MDMA HCl, or they received initial and supplemental doses of inactive placebo. Psychotherapists and independent raters were blinded to participants' treatment conditions. This treatment period also consisted of non-drug preparatory therapy sessions and non-drug integration therapy sessions.
During Stage 2 of the study, the blind was broken and participants assigned to receive MDMA-assisted therapy in Stage 1 underwent a third open-label experimental session of MDMA-assisted therapy. Participants assigned placebo with therapy during Stage 1 who chose to enroll in Stage 2 underwent three open-label sessions of MDMA-assisted therapy. Outcome measures were administered two months after the second experimental session in Stage 1 and four to six weeks after the second MDMA-assisted therapy session in Stage 2. A final data-collection session took place at two months after the third experimental session.
The primary objective of the study was to measure change in PTSD symptoms via CAPS-IV across the study in participants receiving MDMA-assisted therapy versus placebo with therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
They must either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2 to 2.5 hours later by a second dose of 62.5 mg midomafetamine HCl during two 8-hour long blinded therapy sessions.
Drug: Midomafetamine HCl · Behavioral: Therapy
Participants will receive an initial dose of 125 mg placebo orally followed 2 to 2.5 hours later by a second dose of 62.5 mg placebo during two 8-hour long blinded therapy sessions.
Drug: Lactose placebo pill · Behavioral: Therapy
125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl
Also known as: MDMA HCl, 3,4-methylenedioxymethamphetamine, MDMA, Midomafetamine
125 mg followed by a supplemental half-dose of 62.5 mg
Also known as: Placebo
Non-directive therapy provided by a team of two co-therapists
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline to 2 months post second experimental session
Change in Impact of Events Scale Revised (IES-R) From Baseline to 2-month Follow-up
The Impact of Events Scale Revised (IES-R) is a 22-item self-report measure (for DSM-IV) designed to measure the extent to which a given stressful life event produces subjective distress. Each item corresponds directly to 14 of the 17 DSM-IV symptoms of PTSD and is rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely") for the extent to which the item was true for the participant during the past seven days. The IES-R yields a total score ranging from 0 to 88 with higher scores indicated greater distress.
Time frame: Baseline to 2 months post second experimental session
Participants were recruited via letters to psychotherapists and internet advertisements.
| Milestone | MDMA-assisted Therapy | Placebo With Therapy |
|---|---|---|
| Started | 15 | 8 |
| Completed | 13 | 8 |
| Not completed | 2 | 0 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | MDMA-assisted Therapy | Placebo With Therapy |
|---|---|---|
| Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up | -55.2 ± 33.54 | -20.5 ± 20.47 |
The Impact of Events Scale Revised (IES-R) is a 22-item self-report measure (for DSM-IV) designed to measure the extent to which a given stressful life event produces subjective distress. Each item corresponds directly to 14 of the 17 DSM-IV symptoms of PTSD and is rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely") for the extent to which the item was true for the participant during the past seven days. The IES-R yields a total score ranging from 0 to 88 with higher scores indicated greater distress.
| score on a scale | MDMA-assisted Therapy | Placebo With Therapy |
|---|---|---|
| Change in Impact of Events Scale Revised (IES-R) From Baseline to 2-month Follow-up | -29.7 ± 21.3 | -12.9 ± 15.00 |
Collected over On or after first day of study intervention through to follow-up visit (approximately 7 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MDMA-assisted Therapy | 0/15 (0%) | 2/15 (13.3%) | 13/15 (86.7%) |
| Placebo With Therapy | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| SRRs: MDMA-assisted Therapy | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| SRRs: Placebo With Therapy | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Event | MDMA-assisted Therapy | Placebo With Therapy | SRRs: MDMA-assisted Therapy | SRRs: Placebo With Therapy |
|---|---|---|---|---|
| Clavicle fractureMusculoskeletal and connective tissue disorders | 1/15 | 0/8 | — | — |
| SyncopeNervous system disorders | 1/15 | 0/8 | — | — |
| Event | MDMA-assisted Therapy | Placebo With Therapy | SRRs: MDMA-assisted Therapy | SRRs: Placebo With Therapy |
|---|---|---|---|---|
| AnxietyPsychiatric disorders | 2/15 | 4/8 | 14/14 | 8/8 |
| FatigueGeneral disorders | 4/15 | 2/8 | 14/15 | 8/8 |
| HeadacheNervous system disorders | 1/15 | 0/8 | 13/14 | 8/8 |
| InsomniaPsychiatric disorders | 0/15 | 1/8 | 12/13 | 8/8 |
| FatigueGeneral disorders | 0/15 | 0/8 | 14/15 | 8/8 |
| Increased irritabilityGeneral disorders | 0/15 | 0/8 | 8/12 | 7/8 |
| NauseaGastrointestinal disorders | 1/15 | 0/8 | 11/15 | 6/7 |
| Jaw clenching, tight jawGeneral disorders | 0/15 | 0/8 | 12/14 | 6/8 |
| NauseaGeneral disorders | 0/15 | 0/8 | 11/15 | 6/7 |
| DizzinessNervous system disorders | 1/15 | 0/8 | 8/14 | 6/8 |
| Age, Continuous(years) | MDMA-assisted Therapy | Placebo With Therapy | Total |
|---|---|---|---|
| Mean | 40.5 ± 7.4 | 40.8 ± 7.0 | 40.6 ± 70.1 |
| Sex: Female, Male(Participants) | MDMA-assisted Therapy | Placebo With Therapy | Total |
|---|---|---|---|
| Female | 11 | 7 | 18 |
| Male | 4 | 1 | 5 |
| Race/Ethnicity, Customized(Participants) | MDMA-assisted Therapy | Placebo With Therapy | Total |
|---|---|---|---|
| Caucasian | 14 | 8 | 22 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2004, a primary completion of May 2008 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2021, 13 years 5 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Stress Disorders, Post-Traumatic →